Mebendazole as Adjuvant Treatment for Colon Cancer

NCT ID: NCT03925662

Last Updated: 2019-04-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-01

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

mebendazole treating colon cancer

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

mebendazole as adjuvant treatment for colon cancer

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Folfox with avastin

Folfox with avastin only

Group Type ACTIVE_COMPARATOR

Folfox with avastin

Intervention Type DRUG

Folfox with avastin only

Mebendazole

Folfox with avastin with mebendazole

Group Type EXPERIMENTAL

Mebendazole

Intervention Type DRUG

Folfox with avastin with mebendazole

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Folfox with avastin

Folfox with avastin only

Intervention Type DRUG

Mebendazole

Folfox with avastin with mebendazole

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

folfox 4 mebendazol

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Colorectal cancer stage 4.

Exclusion Criteria

* Agranulocytosis
* Pregnancy
* Allergy to mebendazole.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sherief Abd-Elsalam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sherief Abd-Elsalam

Ass. Prof. Tropical Medicine

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Reham El-ghoneimy, Msc

Role: PRINCIPAL_INVESTIGATOR

Tanta University - Faculty of Pharmacy

Sahar Hegazy, Prof

Role: PRINCIPAL_INVESTIGATOR

Tanta University - Faculty of Pharmacy

Gamal el-azab, Prof

Role: STUDY_DIRECTOR

Tanta University - Faculty of Pharmacy

Fatma Zakaria, Prof

Role: STUDY_CHAIR

Tanta University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sherief Abd-Elsalam

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sherief Abd-Elsalam, ass. prof.

Role: CONTACT

00201147773440

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sherief Abd-elsalam, lecturer

Role: primary

00201000040794

References

Explore related publications, articles, or registry entries linked to this study.

Hegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022 Jun 15;299:120536. doi: 10.1016/j.lfs.2022.120536. Epub 2022 Apr 3.

Reference Type DERIVED
PMID: 35385794 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

colon cancer

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

D,L-MEthadone and mFOLFOX6 in Treatment of Advanced Colorectal Cancer
NCT05212012 ACTIVE_NOT_RECRUITING PHASE1/PHASE2